Compare Stocks: KMDA, PVLA, ZYME, and BHVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$12.11 +1.5%	$13.97	$7.48 ▼ $18.57	$1.82B	1.35	2.65 million shs	1.37 million shs
KMDA Kamada	$8.08 +3.9%	$8.10	$6.55 ▼ $9.35	$464.64M	0.89	119,583 shs	72,765 shs
PVLA Palvella Therapeutics	$138.77 +5.7%	$147.99	$65.93 ▼ $161.38	$2.00B	-0.27	236,962 shs	174,037 shs
ZYME Zymeworks	$25.79 +2.1%	$26.64	$16.00 ▼ $31.34	$1.83B	1.17	1.00 million shs	491,135 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+1.25%	-6.01%	-19.41%	-22.39%	-21.19%
KMDA Kamada	+3.86%	-2.77%	-1.58%	+13.48%	+18.13%
PVLA Palvella Therapeutics	+5.66%	+4.76%	-8.31%	-4.14%	+85.40%
ZYME Zymeworks	+2.10%	+2.54%	-5.01%	-0.35%	+54.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$12.11 +1.5%	$13.97	$7.48 ▼ $18.57	$1.82B	1.35	2.65 million shs	1.37 million shs
KMDA Kamada	$8.08 +3.9%	$8.10	$6.55 ▼ $9.35	$464.64M	0.89	119,583 shs	72,765 shs
PVLA Palvella Therapeutics	$138.77 +5.7%	$147.99	$65.93 ▼ $161.38	$2.00B	-0.27	236,962 shs	174,037 shs
ZYME Zymeworks	$25.79 +2.1%	$26.64	$16.00 ▼ $31.34	$1.83B	1.17	1.00 million shs	491,135 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+1.25%	-6.01%	-19.41%	-22.39%	-21.19%
KMDA Kamada	+3.86%	-2.77%	-1.58%	+13.48%	+18.13%
PVLA Palvella Therapeutics	+5.66%	+4.76%	-8.31%	-4.14%	+85.40%
ZYME Zymeworks	+2.10%	+2.54%	-5.01%	-0.35%	+54.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	2.59	Moderate Buy	$18.69	54.38% Upside
KMDA Kamada	3.00	Buy	$13.50	67.08% Upside
PVLA Palvella Therapeutics	2.93	Moderate Buy	$209.14	50.71% Upside
ZYME Zymeworks	2.77	Moderate Buy	$40.64	57.57% Upside

Current Analyst Ratings Breakdown

Latest KMDA, PVLA, ZYME, and BHVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
10/8/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy
10/7/2026	ZYME Zymeworks	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $34.00
9/29/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$38.00 ➝ $39.00
9/29/2026	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$34.00
9/25/2026	PVLA Palvella Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/22/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
9/21/2026	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$240.00
9/18/2026	KMDA Kamada	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
9/18/2026	BHVN Biohaven	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/17/2026	ZYME Zymeworks	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
KMDA Kamada	$180.46M	2.57	$0.61 per share	13.23	$4.68 per share	1.73
PVLA Palvella Therapeutics	$42.81M	46.71	N/A	N/A	$2.36 per share	58.80
ZYME Zymeworks	$105.96M	17.27	N/A	N/A	$3.59 per share	7.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	21.26	13.93	0.68	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
PVLA Palvella Therapeutics	-$41.72M	-$4.83	N/A	N/A	N/A	N/A	-47.84%	-38.33%	11/10/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	25.53	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest KMDA, PVLA, ZYME, and BHVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ZYME Zymeworks	$2.29	N/A	N/A	N/A	$227.39 million	N/A
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/4/2026	Q2 2026	PVLA Palvella Therapeutics	-$1.17	-$1.52	-$0.35	-$1.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.12	1.49%	N/A	31.58%	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Latest KMDA, PVLA, ZYME, and BHVN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	21.23	4.73	4.73
KMDA Kamada	N/A	4.06	2.29
PVLA Palvella Therapeutics	N/A	21.18	21.18
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
KMDA Kamada	20.38%
PVLA Palvella Therapeutics	40.11%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	13.80%
KMDA Kamada	36.10%
PVLA Palvella Therapeutics	17.20%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	274	151.04 million	130.20 million	Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable
PVLA Palvella Therapeutics	29	14.41 million	11.93 million	N/A
ZYME Zymeworks	264	70.96 million	47.18 million	N/A

KMDA, PVLA, ZYME, and BHVN Headlines

Recent News About These Companies

Zymeworks (NASDAQ:ZYME) EVP Adam Schayowitz Sells 13,832 Shares of Company Stock

October 10 at 5:52 AM | insidertrades.com

Zymeworks (NASDAQ:ZYME) Stock: Insider Adam Schayowitz Sells 13,832 Shares

October 9 at 7:07 PM | marketbeat.com

Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO Hire

October 9 at 6:00 AM | finance.yahoo.com

Zymeworks (NASDAQ:ZYME) Stock Price Up 4.4% - Should You Buy?

October 7 at 12:39 PM | marketbeat.com

Zymeworks stock gains 4.85 percent after 2026 outlook update

October 5, 2026 | ad-hoc-news.deA

Zymeworks stock fell 3.12 percent after Theravance deal closes

October 4, 2026 | ad-hoc-news.deA

Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

October 2, 2026 | marketbeat.com

Zymeworks (NASDAQ:ZYME) Stock Picked Up by Analysts at TD Cowen

October 1, 2026 | americanbankingnews.com

Copertura su Zymeworks ripristinata con Buy da TD Cowen sull’acquisizione

September 29, 2026 | it.investing.com

Zymeworks (NASDAQ:ZYME) Stock Rated "Buy" in New Coverage at TD Cowen

September 29, 2026 | marketbeat.com

Zymeworks raises 2026 guidance after closing Theravance acquisition

September 28, 2026 | streetinsider.com

Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

September 28, 2026 | finance.yahoo.com

Zymeworks Inc. Updates Earnings Guidance for the Year 2026

September 28, 2026 | marketscreener.comM

Zymeworks Appoints Stuart Knight as Executive Vice President & Chief Information Officer

September 28, 2026 | marketscreener.comM

Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow

September 28, 2026 | seekingalpha.com

Zymeworks Issues Updated 2026 Financial Guidance

September 28, 2026 | rttnews.com

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

September 28, 2026 | globenewswire.com

Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME

September 28, 2026 | marketbeat.com

Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger

September 26, 2026 | kalkinemedia.comK

Vancouver biotech Zymeworks closes US$929M Theravance deal

September 24, 2026 | vancouverisawesome.comV

Zymeworks Completes Acquisition of Theravance Biopharma

September 23, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, PVLA, ZYME, and BHVN Company Descriptions

Biohaven NYSE:BHVN

$12.10 +0.18 (+1.47%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$12.10 -0.01 (-0.08%)

As of 10/9/2026 07:30 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Kamada NASDAQ:KMDA

$8.08 +0.30 (+3.86%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$8.09 +0.01 (+0.12%)

As of 10/9/2026 07:56 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Palvella Therapeutics NASDAQ:PVLA

$138.77 +7.43 (+5.66%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$138.62 -0.15 (-0.11%)

As of 10/9/2026 06:57 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Zymeworks NASDAQ:ZYME

$25.79 +0.53 (+2.10%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$25.79 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KMDA, PVLA, ZYME, and BHVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KMDA, PVLA, ZYME, and BHVN Earnings

Compare Dividends

Latest KMDA, PVLA, ZYME, and BHVN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KMDA, PVLA, ZYME, and BHVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, PVLA, ZYME, and BHVN Company Descriptions

Biohaven NYSE:BHVN

Kamada NASDAQ:KMDA

Palvella Therapeutics NASDAQ:PVLA

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KMDA, PVLA, ZYME, and BHVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KMDA, PVLA, ZYME, and BHVN Earnings

Compare Dividends

Latest KMDA, PVLA, ZYME, and BHVN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KMDA, PVLA, ZYME, and BHVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, PVLA, ZYME, and BHVN Company Descriptions

Biohaven NYSE:BHVN

Kamada NASDAQ:KMDA

Palvella Therapeutics NASDAQ:PVLA

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools